Hours after blockbuster patent win, Mylan asks the FDA to speed up an OK to market a generic to Biogen’s Tecfidera
Hours after Biogen was handed a key defeat in federal court, losing patent protection that would have protected the multibillion-dollar franchise drug Tecfidera to 2028, Mylan jumped in with a plan to ask the FDA for an accelerated OK of its copycat drug.
Looking at carving up a market that delivered $4.4 billion of Biogen’s revenue last year — 39% of the big biotech’s total — Mylan doesn’t want to wait 5 months for a scheduled decision from the agency.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.